Tests RO7568282 against placebo in early-stage Parkinson's disease
Tests RO7568282 against placebo in adults with early Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
Key facts
- Where
- Cork, Dublin 7, and Dublin 8, IrelandSee the 3 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 85 with early-stage idiopathic Parkinson's disease who take a stable dose of levodopa alone.
- Age
- 40 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Idiopathic Parkinson's disease, Hoehn and Yahr stage 3 or lower (assessed off medication), MDS-UPDRS Part IV score of 0.
- Earlier treatment
- Must have taken stable doses of levodopa alone for at least 2 months before baseline.
Main reasons for not taking part
- Parkinsonian syndrome other than idiopathic Parkinson's disease
- Parkinson's disease dementia
- Significant neurologic disease other than Parkinson's disease
- Unstable or clinically significant cardiovascular disease within the last year
- Chronic uncontrolled hypertension
Read by machine on 10 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
- Has a doctor told you that you have a different condition with similar signs, such as multiple system atrophy or progressive supranuclear palsy?
- Which medicine do you take for Parkinson's disease now?
- Do you have dementia, or serious problems with memory and thinking?
Source: NCT07781644, who can take part
Where in Ireland
- Cork University HospitalCork, IrelandNot yet recruiting
- Mater Misericordiae University HospitalDublin 7, IrelandNot yet recruiting
- St James's HospitalDublin 8, IrelandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07781644EU 2025-524064-37-00
- Record updated
- 9 November 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of RO7568282 compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.Read full original descriptionShow less
A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants With Early-stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of RO7568282 compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Inclusion: Must be aged 40 to 85 years inclusive; Diagnosis of idiopathic PD; Has received stable doses of monotherapy treatment with levodopa for at least 2 months prior to baseline; Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV score of 0 at screening and prior to randomization at baseline; Hoehn and Yahr (H\&Y) Stage ≤ 3 (assessed in off medication state) at screening and prior to randomization at baseline; Able to swallow whole capsules.
Exclusion: Medical history indicating a parkinsonian syndrome other than idiopathic PD; Diagnosis of PD dementia; Diagnosis of a significant neurologic disease other than PD; Within the last year, unstable or clinically significant cardiovascular disease; Chronic uncontrolled hypertension; History or presence of brain magnetic resonance imaging (MRI) scan showing evidence of structural abnormalities, other than related to PD; Note: Other protocol-defined inclusion/exclusion criteria also apply.